Abstracts from four Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, June 3-7 at the McCormick Place in Chicago. The studies include GU12-157 (poster session), GU14-188 (poster session), GU14-202 (poster session), and LUN14-179 (publication-only abstract).

GU12-157

Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157. See abstract.

• Type: Poster Session
• Time: Monday, June 6, 1:00 – 4:30 p.m. CT
• Location: Hall A
• Abstract Number: 4526
• Poster Board Number: 149
• Citation: J Clin Oncol 34, 2016 (suppl; abstr 4526)
• Author(s): Noah M. Hahn, Trinity J. Bivalacqua, Ashley Ross, George J. Netto, Jong Chul Park, Timothy A. Masterson, Michael O. Koch, Richard Bihrle, Richard Foster, Thomas A. Gardner, Liang Cheng, David R Jones, Kyle McElyea, George Sandusky, Ziyue Liu, Scott A Turner, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, Daniel M. Geynisman; Johns Hopkins Kimmel Cancer Center, Baltimore, MD; The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD; Johns Hopkins University School of Medicine, Baltimore, MD; The Johns Hopkins Medical Institutions, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN; Division of Biostatistics, Indiana University, Indianapolis, IN; Dartmouth Giesel School of Medicine, Lebanon, NH; The Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH; Fox Chase Cancer Center, Philadelphia, PA

 

GU14-188

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC). See abstract.

• Type: Poster Session
• Time: Monday, June 6, 1:00 – 4:30 p.m. CT
• Location: Hall A
• Abstract Number: TPS4578 (trials in progress abstract)
• Poster Board Number: 198a
• Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS4578)
• Author(s): Christopher J. Hoimes, Robert Abouassaly, Joel N. Saltzman, Mark T. Fleming, Jean H. Hoffman-Censits, Tara Byrd, Cheryl Eitman, Michele Snyder-Willis, Jodi O’Neill, Lisa Wood, Robin Elliott, Matthew M. Cooney; Case Comprehensive Cancer Center at Seidman Cancer Center, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; US Oncology Research, Virginia Oncology Associates, Hampton, VA; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Seidman Cancer Center at Lake, Cleveland, OH; Hoosier Cancer Research Network, Indianapolis, IN; Dept of Pathology, UH-Case Medical Center, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

 

GU14-202

Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202. See abstract.

• Type: Poster Session
• Time: Saturday, June 4, 1:00 – 4:30 p.m. CT
• Location: Hall A
• Abstract Number: TPS5095 (trials in progress abstract)
• Poster Board Number: 441a
• Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS5095)
• Author(s): John Paul Flores, Paul Mathew; Tufts Medical Center, Boston, MA

 

LUN14-179

Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179. See abstract.

• Type: Publication-only abstract
• Abstract Number: e20025
• Citation: J Clin Oncol 34, 2016 (suppl; abstr e20025)
• Author(s): Greg Andrew Durm, Ebenezer A. Kio, William B. Fisher, Michael L. Titzer, Salma Jabbour, TIM Breen, Ziyue Liu, Nasser H. Hanna; Indiana University Simon Cancer Center, Indianapolis, IN; Goshen Center for Cancer Care, Goshen, IN; Indiana University Health Ball Memorial Hospital, Muncie, IN; Oncology Hematology Associates of Southwest Indiana, Newburgh, IN; Cancer Inst of New Jersey Robert Wood Johnson Univ Hosp, New Brunswick, NJ; Hoosier Cancer Research Network, Indianapolis, IN; Division of Biostatistics, Indiana University, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

 

Attending ASCO? Stop by the HCRN Booth (#25099) in McCormick Place South, Exhibit Hall A.
 

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,600 subjects have participated in Hoosier Cancer Research Network clinical trials.